The Canary Medical Team

Inventor with over 200 patents and patent applications, involved in the discovery and development of the TAXUS® Drug-Eluting Coronary Stent, the Zilver PTX Peripheral Drug-Eluting Stent, and the Quill barbed wound closure device; used in over 40 million patients and recorded revenues of over $25 billion

Board of Directors

Jim Karkanias’ background spans science (neuroscience), engineering (bioengineering, codedevelopment), technology (neuralnets, machine learning, robotics) and business (founder of a software startup in the 90’s and then head of clinical operations for the human health division at Merck).

He held the role of Partner at Microsoft for the past decade, leading Program Management for Information Management and Machine Learning in the Cloud + Enterprise Division.

As senior director of data sciences at CZ Biohub, and in collaboration with partners at Berkeley, Stanford, UCSF, and the Chan Zuckerberg Initiative, Karkanias aims to build a world-class Data Science team to help drive and support advances in bioinformatics, computational biology, image processing, and next generation analytics.

Dr. Isaac Kohane is the inaugural Chair of the Department of Biomedical Informatics at Harvard Medical School. He develops and applies computational techniques to address disease at multiple scales.

Kohane’s i2b2 project is currently deployed internationally to over 120 major academic health centers to drive discovery research in disease and pharmacovigilance (including providing evidence on drugs which ultimately contributed to “black boxing by the FDA).

Dr. Khaled El Emam is the founder of Privacy Analytics Inc.

He helped found five companies involved with data management and data analytics. Khaled is also a senior scientist at the Children’s Hospital of Eastern Ontario (CHEO) Research Institute and Director of the multi-disciplinary Electronic Health Information Laboratory (EHIL) team, conducting academic research on de-identification and re-identification risk.

He is a world-renowned expert in statistical de-identification and re-identification risk measurement. He is qualified to anonymize Protected Health Information under the HIPAA Privacy Rule.

CEO and Partner at Quark Venture Inc., a venture capital investment firm.

She most recently led The Centre for Drug Research and Development (CDRD) as President and CEO.

Karimah Es Sabar has 30 years of dynamic global business experience.

She previously led LifeSciences BC, and has also held senior management positions with international multinational companies.

Canary Project Team

Former SVP R&D/CTO CareFusion, SVP R&D Angiotech, and executive R&D roles at Medtronic,

30 years medical device R&D, Commercialization, and M&A experience with over 40 patents & patents pending

20 years experience Orthopedic Marketing/Consulting/ Product Development, Knee Society Member

Author of Numerous Orthopedic Textbooks/ Peer Reviewed Research Papers, Established Orthopedic Educator both national and international, Former Director ISK Institute, Design Surgeon Journey 2 prosthesis

Zimmer President of the Americas and responsible for the largest orthopedic acquisition in US history worth 19B.

30+ years of orthopedic executive management, medical devices and sales expertise.

Canary Scientific Advisors

Leading world expert on ambulatory methods to assess subjective experience & physiology, use of ambulatory interventions.

President of the International Society for Ambulatory Assessment

Author of + 200 scientific articles

Leading world expert in health psychology (e.g. coping with stressful life experiences)

Over 18,000 citations to his research

Canary Consultants

Developer of IoT Big Data solutions via software as a service

Former head of RA at Medtronic

Former FDA CDER Branch Division Chief